JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
![Foto de JOSÉ ÁNGEL](/img/nophoto.png)
![Foto de Hospital Severo Ochoa](/img/noimage_org.png)
Hospital Severo Ochoa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Severo Ochoa (11)
2024
-
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Cancers, Vol. 16, Núm. 2
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
2023
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
2021
-
Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study
HemaSphere, Vol. 5, Núm. 3, pp. 1-8
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2017
-
Further psychometric validation of the GAH scale: Responsiveness and effect size
Journal of Geriatric Oncology, Vol. 8, Núm. 3, pp. 211-215
2015
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211